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ABSTRACT 
 
The kidney glomerulus is essential for the filtration of waste products from the blood 
into the urine and in controlling the volume and composition of body fluids.  Injury to 
the glomerulus can lead to altered glomerular filtration rate, proteinuria, thickening of 
the glomerular basement membrane (GBM) and accumulation of mesangial cell matrix. 
The injuries can occur due to primary kidney diseases or as a secondary effect of other 
diseases such as diabetes mellitus. The blood-brain barrier (BBB) differs in many ways 
from of the glomerular filtration barrier. While glomerular endothelial cells are 
fenestrated and highly permeable, the endothelial cells of the blood-brain barrier are 
continuous and held together by tight junctions. Passage across the BBB is tightly 
controlled and serves to protect the neuronal tissue of the central nervous system from 
fluctuations in hormones, nutrients, metabolites and other substances in the blood. 
The targeted deletion of either platelet-derived growth factor-B (PDGF-
B) or PDGFR- β is embryonic lethal due to cardiovascular complications and lead to a 
failure in recruiting pericytes to the developing vasculature and mesangial cells into the 
glomerulus. In paper I we investigated the role of endothelium-derived PDGF-B in the 
recruitment of pericytes and mesangial cells using a mouse model with a targeted 
conditional deletion of PDGF-B in endothelial cells. We found that the phenotype 
mimics that of the null mutation, but is much milder. Thus the endothelium appears to 
be the main source of PDGF-B in the vasculature.  
In the kidney, the initial deficiency of glomerular mesangial cells normalized soon after 
birth and later led to a very light albuminuria and enlargement of the glomeruli. To 
increase our knowledge of the glomerular transcriptome we constructed a cDNA array 
from isolated mouse glomeruli.  
In paper II we used it to identify a number of novel glomerular 
transcripts. In a series of experiments these transcripts were assigned to specific cell 
types and characterized as podocyte or mesangial cell/juxtaglomerular markers. Further 
study on podocyte marker Foxc2 revealed a role in podocyte differentiation and 
glomerular development. 
In paper III we used several pericyte deficient mouse models to elucidate 
the role of pericytes in the integrity of the BBB. We found a correlation between the 
degree of pericyte deficiency and the extravasation of injected tracers across the BBB 
via macromolecular trancytosis, for the first time in vivo demonstrating the importance 
of pericytes in maintaining the BBB function. 
To gain insight into the transcriptional changes behind diabetes-related 
glomerular injury, we analyzed kidney function and gene expression in the db/db 
mouse, a model of type 2 diabetes. We found increased expression of genes relating to 
the infiltration of monocytes/macrophages into the glomerulus, changes in expression 
of genes involved in the composition of the GBM and the extracellular matrix, as well 
as in signal transduction and growth factor expression. We also noted strong and 
consistent upregulation of Ym-1, a marker for alternatively activated macrophages 
(aaMac). Further analysis of our data set revealed that expression of several markers for 
aaMac were upregulated, while markers for classically activated macrophages 
remained unaltered.  
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INTRODUCTION 
  
1.1 THE GLOMERULUS 
 
1.1.1 The function of the kidney 
The most important function of the kidney is to rid the body of waste materials, either 
ingested or produced by metabolism. A second important function is to control the 
volume and composition of the body fluids. The regulation of water and electrolytes by 
the kidneys is what maintains a stable environment for the cells in our bodies, so that 
they can perform their various tasks. Other important features of the kidneys also 
include: 
 Regulating acid-base balance by excreting acids and regulating the body fluid 
buffer stores  
 Regulate arterial blood pressure in the long term by regulating sodium and 
water excretion and in the short term by secreting vasoactive factors such as 
renin  
 Produce, secrete and regulate hormones involved in the production of red blood 
cells and the active form of vitamin D  
 Regulate blood glucose levels during prolonged fasting by gluconeogenesis [1] 
 
The filtration unit of the kidney is the nephron, where a large amount of plasma is 
filtered in a tuft of capillary in the glomerulus and is converted into urine in the long 
tubule on its way to the renal pelvis. Each human kidney contains about one million 
nephrons. The kidney can’t regenerate nephrons lost due to renal injury, disease or 
normal aging. The glomerulus is a network of branching and anastomosing capillaries 
with high hydrostatic pressures, leading to effective filtration. In a healthy kidney only 
water, various solutes and small proteins can pass through the glomerular filtration 
barrier. If the barrier is disrupted, as is the case in various nephropathies, 
macromolecules such as albumin leak to the primary urine. The tubular system is very 
effective in concentrating the primary urine by reabsorbing substances such as ions and 
small proteins, but fails to absorb larger proteins, causing them to remain in the final 
urine. This is called proteinuria, or more specifically albuminuria, referring to the 
leakage of the plasma protein albumin. 
 
1.1.2 The glomerular filtration barrier  
The glomerular filtration barrier consists of three layers: fenestrated glomerular 
endothelial cells, the glomerular basement membrane (GBM) and the highly 
specialized epithelial podocytes. Data shows that all three layers need to be intact for 
functional filtration [2, 3]. 
 
The glomerular endothelial cells are highly fenestrated to allow the passage of large 
volumes of water and solvents across the endothelial barrier [4]. The fenestrations in 
the glomerulus lack diaphragms, making them too large to effectively filter large 
macromolecules. However, the endothelial cells have a coating of glycocalyx 
composed of negatively charged glycoproteins, aminoglycans and protoglycans [5]. 
This layer probably provides a charge-selective function to the glomerular barrier, since 
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it has been shown that degradation of the endothelial glycocalyx layer results in an 
increased urinary output of albumin [6].  
 
The glomerular basement membrane (GBM) is a fibrous network of type IV collagen, 
nidogen/entactin, laminin, nidogen/entactin together with proteoglycans such as agrin 
and perlecan and glycoproteins. The collagen IV network can be described as the 
backbone of the membrane and mutations in collagen IV chains give rise to severe 
pathlogical conditions such as Alport syndrome (hereditary glomerulonephritis) [7, 8]. 
The large amount of negatively charged heparin sulphate proteoglycans in the GBM 
has lead to the hypothesis that the negative charge of the barrier would work as a 
charge-selective barrier by repelling negatively charged plasma proteins and thus 
preventing them from passing the GBM [9, 10]. Lately this theory has been challenged 
since it has been shown that transgenic mice lacking agrin, the major heparin sulphate 
proteoglycan of the GBM, do not develop proteinuria [11, 12]. In another experiment it 
has also been shown that there was no difference in the sieving curves for negatively 
charged Ficoll versus neutral Ficoll in isolated GBMs [13]. These experiments suggest 
that the majority of the charge-selective barrier lies in the endothelial or epithelial 
layers.  
 
The visceral epithelial cells known as podocytes line the outside of the GBM and wrap 
around the glomerular capillaries. They are highly specialized cells with large cell 
bodies and multiple, long foot processes. The foot processes are separated by a 
filtration slit that is 25-60 nm wide and covered by a diaphragm. The slit diaphragm 
consists of a complex of proteins and forms a zipper-like structure that bridges the foot 
processes, making it permeable to water and solvents but relatively impermeable to 
plasma proteins [14, 15]. The proteins in the slit diaphragm have been extensively 
studied [16-20] and some of them, such as nephrin have been shown to be vital for the 
maintenance of normal glomerular filtering selectivity. Mutations in nephrin cause 
massive proteinuria in patients suffering from congenital syndrome of the Finnish type 
[21-23]. 
 
 
1.1.3 Assessing kidney function  
Urine formation results from glomerular filtration, tubular reabsorption and tubular 
secretion. The blood is first filtered in the glomerulus where the high hydrostatic 
pressure pushes fluid from the blood across the filtration barrier and into the Bowman’s 
capsule. Since most low molecular-weight substances of the plasma are freely filtered 
their concentrations in primary urine are almost the same as in the plasma. The filtered 
fluid then passes through the capsule into the tubule and its composition is modified by 
tubular reabsorption and secretion until the final urine leaves the nephron, passes 
through the collecting ducts into the renal pelvis and leaves the kidney through the 
ureter. Examples of tubular reabsorption are water and many electrolytes such as 
sodium, which are partially reabsorbed. Nutrients such as amino acids and glucose are 
filtered but not excreted into the urine, because in a healthy individual all of the filtered 
nutrients are reabsorbed in the tubuli. Some substances, such as potassium and 
hydrogen ions, are filtered by the glomerulus and also secreted by the tubule, thus 
causing the substance to be rapidly cleared from the blood. The rate at which a 
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substance is cleared from the blood and excreted in the urine depends on the relative 
rate of filtration, absorption and excretion for that particular substance [1].  
 
In the classification of diabetic kidney disease, two main methods are used. The first is 
the classification system by Mogensen based on data from patients with type 1 diabetes 
[24, 25] ; the other system is the more general Kidney Disease Quality Outcomes 
Initiative (KDQOI) for classification of chronic kidney disease (CKD) [26]. While their 
classification systems into five stages of CKD are similar, the diabetes-specific 
classification is based on albuminuria while the more general classification system uses 
glomerular filtration rate as a measurement of kidney disease severity.  
 
Clinically, glomerular filtration rate (GFR) is generally accepted as the best over all 
measure of kidney function [27]. GFR is measured as the clearance of an inert filtration 
marker that is filtered by the glomeruli but neither absorbed nor excreted by the tubuli. 
Common exogenous markers to be used are inulin or EDTA. However, measuring GFR 
using exogenous markers is too expensive and too complex for routine clinical practice. 
Urinary clearance of an endogenous marker can be calculated from blood samples and 
timed urine collection. Collecting urine over 24-hour periods is tedious, and since there 
is a relationship between the serum level of an endogenous marker and the level of 
GFR, GFR is normally estimated without urine collection. One of the most commonly 
used endogenous markers is creatinine, an amino acid derivative released by muscle 
cells. Many studies support the similarity of creatinine clearance to GFR and its 
reciprocal relationship with the serum creatinine level [28, 29]. Creatinine is secreted 
by tubular cells, so the measured creatinine clearance will exceed GFR. There is also 
some inter and intra-individual variation, especially when there is a mild to moderate 
reduction in GFR [30]. Different equations used to estimate GFR may cause analytical 
bias [31]. Another possible endogenous marker under investigation is Cystatin C, a 
small protein that is freely filtered and later reabsorbed and catabolised by tubular 
epithelial cells [32]. In some hospitals a combination of creatinine and cystatin C is 
used to get a more reliable estimation of GFR [33].  
 
Another way to asses kidney function is to look for albuminuria, the leakage of 
albumin into the urine. This is sometimes referred to as Albumin Excretion Rate (AER) 
and is usually done quite easily with a dip stick. Microalbuminuria is defined as 
passage of 30-300 mg of albumin per 24 hours and macroalbuminuria as >300 mg/24h 
[34]. There is a strong link between micoalbuminuria and early diabetic renal disease 
where microalbuminuria usually indicates the beginning of diabetic nephropathy [35-
37]. Albuminuria has also been shown to predict mortality in both type 1 diabetes [38] 
and type 2 diabetes [39] because it is linked to cardiovascular disease. Traditionally, 
increased in AER to above 300 mg/24h has been considered to indicative of the onset 
of a decreased GFR. But when exogenous markers for GFR have been used rather than 
formulas to calculate GFR from serum creatinine, a decrease in GFR has been seen 
already at microalbuminuric levels. It has been suggested that both GFR and AER 
should be assessed in the staging of diabetic nephropathy [34]. 
 
Transgenic mouse models or rodents with experimentally induced diabetes are 
frequently used to study kidney function, and the models most commonly used to study 
diabetic complications will be discussed in more detail below. However, assessing 
 4 
kidney functions in rodents require some methodologies that are different from the ones 
used on human patients in the clinic.  
Blood sampling to test for blood glucose in mice should ideally be done in the fasting 
state to rule out fluctuations due to recent feeding. Since mice and rats are nocturnal 
eaters, removing the food during night would result in a prolonged fast of almost 24 
hours. A standard protocol developed by the National Institutes of Health (NIH) 
suggests removing the chow at 7 am, fasting the animals between 7 am and 1 pm, and 
sampling the blood at 1 pm [40, 41]. The relationship between HbA1c (glycosylated 
haemoglobin) and long term glucose control is valid in mice, as well as in humans [42]. 
GFR can be estimated by measuring plasma creatinine, but it has been reported that 
creatinine levels in plasma in mice were greatly overestimated when the Jaffé alkaline 
picrate method was used as opposed to when in the use of HPLC [43]. The assay-
dependent variability in the accuracy of creatinine as a measure of GFR in rodents has 
been noted in other studies using enzymatic tests as well [44]. GFR estimation by inulin 
clearance, the old golden standard, has been adapted for use in rodents using FITC-
labeled inulin [45, 46]. 
Albuminuria measurement is the method most commonly used in rodents to grade the 
severity of DN. Dip stick analysis should be avoided since the method is inaccurate in 
mice, probably due to other proteins present in mouse urine [47, 48]. The Animal 
models of Diabetic Complications Consortium (AMDCC), a NIH consortium, 
recommend to use an ELISA with antibodies raised against mouse albumin and to 
collect urine in metabolic cages for 24 hours [40]. That is the method I have used in 
paper I and IV. Another method to estimate kidney function is to measure the ratio 
between albumin and creatinine in spot urine. In most cases this ratio correlates 
significantly with 24 hour urinary excretion rate (UAE), but not in all genetic 
backgrounds [49]. It should also be noted that the creatinine level should be measured 
with HPLC [43].  
Histopathology is usually done to assess mesangial matrix expansion, general 
glomerular morphology and tubulointerstitial pathology. Hematoxylin and eosin does 
not highlight basement membranes well and does not clearly distinguish between 
cytoplasm and matrix components in mesangial regions. Periodic acid-Schiff (PAS) 
provides crisp basement membranes and capillary loops and easily distinguishable 
mesangial regions. Another, more difficult method is to use silver methenamine 
staining or immunohistochemical staining for collagen IV to visualise basement 
membranes and mesangial matrix [50]. In paper I, I used PAS to visualise mesangial 
matrix and alpha smooth muscle actin (ASMA) to visualise the absence of mesangial 
cells.  
 
Protocols and other resources for phenotyping of mouse models with diabetic 
nephropathy can be found on the AMDCC homepage: http://www.amdcc.org 
 
  
1.2 PERICYTES AND PLATELET-DERIVED GROWTH FACTORS 
1.2.1 Pdgf and Pdgf-receptor biology  
Platelet-derived growth factor (Pdgf) proteins were discovered already in 1974, as a 
platelet-dependent serum factor that promotes the growth of smooth muscle cells and 
fibroblasts in vitro [51, 52]. In 1979 the protein was purified from platelets, 
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characterized and named Pdgf [53, 54]. Pdgf-a, -b, -c and –d are the four ligands that 
form five possible combinations of disulphide-linked dimers, Pdgf-aa, -ab, -bb, -cc and 
–dd. They bind to the Pdgf receptors-α and –β. Pdgf-a and –b are secreted in their 
active form, while Pdgf-c and –d require proteolytic cleavage of their N-terminal CUB 
domain in order to become biologically active [55]. Although a number of ligand-
receptor combinations signal in vitro, only a few appear to have physiological 
significance in vivo namely those of Pdgfaa and –cc over Pdgfrα and Pdgfbb over 
Pdgfrβ [56]. During the embryonic development of the vascular system, Pdgfb is 
mostly expressed by the developing vascular endothelium [57] while Pdgfrβ is 
expressed by vascular smooth muscle cells/pericytes [58].  
 
Targeted deletion of either Pdgfb or Pdgfrβ leads to a failure in recruiting pericytes to 
the developing vasculature and the embryos die at late gestation due to edema, dilation 
of the heart and large blood vessels, capillary haemorrhage and subsequent heart failure 
[57-60]. In targeted conditional deletion of Pdgfb in endothelial cells the phenotype 
mimics that of the null mutation, but is much milder, and the offspring is viable and 
fertile (See Paper II and [61]). Pdgf-a and –b both contain a basic amino acid stretch at 
the c-teminal end of the protein, often called a retention motif. This sequence causes the 
protein to be retained in close proximity to the cell surface and the extra cellular matrix 
instead of diffusing away [62]. The recruitment of pericytes to vessels depends largely 
on the expression of Pdgfb by the endothelial cells and its binding to the Pdgfrβ 
receptor on pericytes. The proper location of Pdgfb is crucial for the pericytes to adhere 
closely to the vessel wall. The positive charges in the retention motif binds to 
negatively charged sulphate groups in the heparin sulphate proteoglycans (HSPGs) of 
the matrix, thus keeping the majority of the secreted protein in close contact with the 
vessels. A gradient is created and this is required for proper investment of pericytes into 
the vessel wall. The role of Pdgfb retention motif was addressed in vivo by deleting the 
motif by targeted mutagenesis [63]. In the Pdgfb retention motif knock-out animals 
(Pdgfb ret/ret), the Pdgfb is unable to bind to the HSPG on the surface of blood vessels 
and is instead freely diffusible, and thus the gradient of Pdgfb surrounding the 
vasculature is disrupted. This leads to a severe reduction in the number of pericytes in 
the vasculature (discussed further in paper III) causing disorganized retinal vasculature, 
retinopathy and in the kidney abnormal, ballooning glomeruli lacking mesangial cells 
and later glomerulosclerosis. Like the endothelial-specific knock-outs, the Pdgfb ret/ret 
mice also survive into adulthood and are valuable in studies of the physiological 
functions of pericytes in postnatal animals. 
 
1.2.2 Pdgf pathology 
In the adult individual Pdgfs are often expressed at low levels, which can be increased 
during stressful situations such as arthrosclerosis and wound healing. Arthrosclerosis is 
viewed as a local chronic inflammation and Pdgf is one of many factors secreted by 
infiltrating immune cells as well as by smooth muscle cells in the vessel wall [64]. 
ApoE-/- mice lacking Pdgfb in circulating monocytes and platelets show a delayed 
formation of smooth muscle cell accumulation in atherosclerotic lesions and 
pharmacological blockade of Pdgf receptors have the same effect [65]. A follow up 
study showed a shift towards a selective pro-inflammatory phenotype in macrophages 
in the sclerotic lesions of ApoE-/- mice lacking Pdgfb in hematopoietic cells [66]. Pdgf-
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a and -b have also been implicated in several fibrotic conditions in the lung (pulmonary 
fibrosis) [67, 68], liver (liver sclerosis) [69, 70], heart (cardiac fibrosis and allograft 
rejection) [71, 72], skin (scleroderma) [73, 74] and kidney (glomerulosclerosis) [63] by 
driving proliferation of myofibroblast-like cells and excessive deposition of 
extracellular matrix (ECM) [56, 75]. 
 
1.2.3 Mesangial cells and Pdgfb in the glomerulus 
As mentioned above, the glomerular filtration barrier has three components; endothelial 
cells, GBM and podocytes. There is, however, another important cell type in the 
glomerulus; the mesangial cells. Mesangial cells are the pericytes of the glomerulus. 
The mesangial cells are situated at the centre of the glomerulus and have several 
important functions including serving as a scaffold for the glomerular vascular tuft, 
generate and control the turnover of mesangial matrix, secrete and act as a target for 
growth factors, provide housekeeping functions and regulation of glomerular capillaries 
as well as play a role in the pathophysiology of many glomerular diseases [76]. 
Mesangial cells can be viewed as the central stalk of the glomerulus and they are in 
continuity with the extraglomerular mesangium and the juxtaglomerular apparatus. 
Like smooth muscle cells, they have contractile abilities and can contract or relax in 
response to vasoactive substances such as Angiotensin II, and thus modify glomerular 
filtration locally [77]. Inside the glomerulus the mesangial cells are in direct cell-cell 
contact with the endothelial cells, with no basement membrane separating the two. The 
mesangial cells generate mesangial matrix, which provides structural support for the 
mesangial cells as well as functions in growth factor sequestration [78]. Mesangial cells 
express Pdgfrβ and need Pdgfb expressed from the glomerular endothelial cells to be 
properly recruited into the glomerulus. In the Pdgfb null mutants the mesangial cells are 
absent from the glomerular core and the complexity of the glomerular tuft is replaced 
by a single capillary loop [79]. This makes the glomeruli appear as a balloon shaped 
structure filled with erythrocytes.  
 
As is discussed in paper I, the endothelium appears to be the main source of Pdgfb in 
the vasculature. When Pdgfb is knocked out from endothelial cells by targeted 
mutagenesis, the phenotype resembles that of  the null mutant but is milder [80]. 
During the first days and weeks postnatally, the number on mesangial cells in the 
glomeruli rapidly increased and at 1 month of age the number of mesangial cells did 
not differ from controls. There was, however, still a slight dilation of both the 
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glomerular cross section and the individual capillary loop diameter. (Paper I, fig 4D-G) 
There was also a small but statistically significant increase in AER in mutants older 
than 12 months. (Paper I, fig 4I) 
 
Not only the presence of Pdgfb, but also the correct spatial localization of Pdgfb is 
crucial for the proliferation and survival of the glomerular mesangial cells. When 
glomeruli from the Pdgfb ret/ret were analysed at late gestation they phenocopied to a 
major extent the characteristic ballooning capillaries of the Pdgfb/Pdgfrβ null mutants. 
The glomeruli lacked all, or almost all, mesangial cells. However, the viability of the 
Pdgfb ret/ret mice offered a unique opportunity to study the postnatal effects of 
mesangial cell loss. As in the conditional endothelial knock-out of Pdgfb (Paper I), by 
postnatal day 5 the number of mesangial cells had increased dramatically in the Pdgfb 
ret/ret and by day 30 the glomeruli were undistinguishable from wild type controls. 
Later, at 6 months of age, the glomeruli showed signs of sclerosis, with fewer 
mesangial cells in the glomerular tuft and excessive mesangial matrix deposition. The 
mice also showed microalbuminuria [63].  
 
Taken together, these data suggest that Pdgfb/Pdgfrβ is essential for the proper 
development of kidney glomeruli and that the system is sensitive to alterations in 
expression levels as well as spatial localization of the Pdgfb protein. 
 
 
  
  
1.3 THE BLOOD-BRAIN BARRIER 
1.3.1 Structure and function of the blood-brain barrier 
The blood-brain barrier (BBB) separates substances in the circulating blood from the 
sensitive cells of the brain. The blood-brain barrier (BBB) differs in many ways from of 
the glomerular filtration barrier. While glomerular endothelial cells are fenestrated and 
highly permeable, the endothelial cells of the BBB are continuous and held together by 
tight junctions. There is still passage over the BBB, but it is tightly controlled and aims 
to maintain a precisely regulated microenvironment that is optimal for neuronal 
signaling. The purpose is to protect the neuronal tissue of the central nervous system 
(CNS) from fluctuations in hormones, nutrients, metabolites and other substances in the 
blood. Adjacent endothelial cells of the BBB are held together by tight junctions (TJs) 
and adherence junctions (AJs), severely restricting the flow of polar solutes in the 
paracellular space and thus separating the blood from the brain extra cellular fluid. [81-
83]. The junctional complexes also confer apical and basal polarity to the cells. One 
other important aspect of the BBB worth mentioning is to separate the 
neurotransmitters and neuroactive substances into two pools – one for the peripheral 
circulation and one for the central nervous system [83]. Only a small number of drugs 
and neuroactive substances are allowed to freely penetrate the BBB and access the 
CNS. Examples of substances allowed free access are small gaseous molecules such as 
oxygen and carbon dioxide and small lipophilic substances including ethanol [82]. 
 
Tight junctions are composed of occludins, claudins and junctional adhesion molecules 
(JAMs) which span the intercellular space and link to the cytoskeleton via regulatory 
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proteins as ZO-1, -2 and -3 and cingulin [84, 85]. Adherence junctions consist of 
cadherin proteins that span the intracellular space and link to the cytoskeleton via α-, β- 
and γ-catenin [84, 85].  
 
1.3.2 BBB pathology 
The BBB is not a fixed structure. The system can be manipulated and the barrier can 
tighten or open up during different conditions.  Many CNS illnesses cause dysfunction 
of the BBB. Multiple sclerosis is characterized by demyelinisation, increased 
permeability of the BBB and the infiltration of inflammatory cells into the CNS. In the 
experimental autoimmune encephalomyelitis model of the illness both ZO-1 and 
occludin had been dysregulated in areas of the brain that show signs of inflammation 
[86-88]. In Alzheimer’s disease the neurotoxic amyliod beta-peptide accumulates in the 
CNS, possibly through deregulated LRP-1/RAGE transport, and causes neurovascular 
inflammation leading to BBB compromise and disturbances in the CNS milieu [89-93]. 
Other illnesses affecting the BBB include Parkinson’s disease [94, 95], epilepsy [96], 
brain tumors [97], inflammation and meningitis [98-100]. 
 
1.3.3 The gliovascular unit and Pdgfb in the BBB 
The specific characteristics of the BBB are formed from interactions between 
endothelial cells, the astrocytic perivascular end-feet and pericytes. Sometimes this 
group of cells is referred to as a gliovascular unit, meaning that no cell is an island, but 
rather the cells interact in developing and maintaining the barrier function of the BBB.  
 
Brain endothelial cells 
are characterized by 
the presence of tight 
junctions, a lack of 
fenestrae and pinocytic 
vacuoles. They are 
selectively permeable 
to molecules with 
suitable mass and 
lipophilicity. The tight 
junctions restrict the 
movement of most 
substances across the 
intercellular space, and 
this means that 
transport from the blood to the interstitial fluid surrounding the brain must take the 
intracellular route and pass through the endothelial cells rather than between them. 
Transport across the endothelial membrane uses for example glucose transporter-1 
(GLUT1) and several amino acid transporters such as L-system for large neutral amino 
acids (LAT1) to supply nutrients to the brain. Some transporters such as GLUT1 and 
LAT1 can be found on both the luminal and abluminal side of the endothelial cell 
[101]. Others, like P-glycoprotein (Pgp) (on the luminal side) or the Na+-dependent 
transporters like excitatory amino acid transporters 1-3 (EAAT1-3) (on the abluminal 
side) are only found on either side of the cell and thus maintain the clear polarization of 
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these cells [102-104]. The endothelial cells secrete a substance called endothelium-
derived leukaemia inhibitory factor (LIF) that induce astrocyte precursor cells to 
differentiate into mature astrocytes [105].   
 
The astrocyte end feet are in close contact with the endothelial cells and the pericytes of 
the BBB, separated only by the basal lamina. The astrocyte end feet provide the cellular 
link to the neurons. They also secrete a number of chemical agents such as 
transforming growth factor-β, glial-derived neurotropic factor and angiopoetin-1 that 
induce BBB-like characteristics by enhancing the barrier function of tight junctions in 
endothelial cells in vitro [106, 107]. The perivascular part of the astrocytic end feet 
expresses aquaporin-4 (Aqp-4) and Kir4.1K+ channels which are important for fluid 
and ion balance in the brain. The Aqp-4 and Kir4.1 channel proteins are arranged in a 
specific pattern called orthogonal arrays of particles (OAPs) at the side of the end feet 
that faces the micro vessel wall and the basal lamina [84, 108]. The localization of 
OAPs and Aqp-4 to the end foot is thought to be dependent on a heparin sulphate 
proteoglycan called agrin in the basal lamina, and agrin has been shown to be important 
for maintaining the barrier function. During pathological conditions when the BBB is 
disrupted, agrin is lost directly indicating the need for agrin in the functional 
polarization of astrocyte end feet [97, 109]. Agrin binds to α-dystroglycan [110]. α-
dystroglycan is a member of a complex called the dystrophin/dystroglycan complex 
and it too localizes to the astrocyte end feet membrane [82]. Another member in the 
dystrophin/dystroglycan complex, α-syntrophin, has been shown to be important for the 
correct localization of Aqp-4 in the perivascular membrane of the end feet [111]. α-
syntrophin also binds Kir 4.1, which explains the co-localization of Kir 4.1 and Aqp-4 
[82].  
 
The pericytes are located in very close proximity to the endothelial cells and the 
astrocyte end feet, sometimes even sandwiched between the two and only separated by 
a thin basal lamina. Little notion has been given to pericytes when the BBB is 
discussed, despite their central location at the gliovascular unit. Not a lot is known 
about their role in maintenance of the BBB function. Studies on pericyte deficient 
mouse models have shown that the absence of pericytes correlates with brain edema 
and brain vascular leakage [112]. In co-culture experiments it has been shown that 
pericytes and endothelial cells, in the presence of astrocytes, are capable of arranging 
themselves into linear capillary-like structures. In the same study the presences of 
pericytes also appear to stabilize the capillary-like structures and prevent endothelial 
cells from going into apoptosis [113]. They may also have a role in regulating TJ 
properties, as brain endothelial cells upregulate the TJ protein occludin in response to 
conditioning with pericyte media. The effect was mediated by pericyte-derived 
Angiopoietin-1 (Ang-1) on the Tie-2 receptor of the endothelial cells [114]. In studies 
where pericytes were co-cultured with endothelial cells, it was shown that pericytes 
significantly reduced the paracellular permeability in cell monolayers [115, 116]. The 
upregulation of the barrier function of the endothelial cells was concluded to be due to 
TGF-β1 expression from the pericytes [115]. Sine PDGF-B is essential for the 
recruitment of pericytes to the vasculature; it seems that mouse models that are 
hypomorphic for PDGF-B would make great tools for studying the effect of pericyte-
deficiency on the BBB. In paper 4 we used two of these models to show that there was 
an increased permeability for tracers across the BBB in mice with low pericyte density.  
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1.4 DIABETES 
1.4.1 Primary and secondary effects of diabetes 
Diabetes Mellitus (DM) is one of the growing illnesses in the western world. It was 
estimated that in the year of 2000 the world wide prevalence of diabetes in all age 
groups was 2,8%, and that by the year of 2030 this will have increased to 4,4% [117]. 
Cardiovascular and renal complications of diabetes accounts for most of the mortality 
and are thought to be due to a complex interplay between metabolic factors, vascular 
constriction and fibrosis as well as inflammation [118, 119].   
 
Type I Diabetes Mellitus (T1DM) also called Insulin Dependent Diabetes Mellitus 
(IDDM) is an autoimmune disorder where the pancreatic β-cells are destroyed, leading 
to a rapid loss of the glucose regulating hormone insulin. It was a lethal illness until 
Banting identified insulin and started experimental treatments with pancreatic extracts 
in the early 1920s [120, 121]. Several immune cells have been found to be involved in 
the β-cell death. In NOD mice, both CD4+ and CD8+ T-cells have an important role in 
the destruction of the β-cells [122], but cells from the innate immune system has also 
been found to play a role in the development of the illness [123-125]. T1DM is 
considered to be under polygenic control, with most of the susceptibility being 
accounted for by variations in the haplotype for human leukocyte antigen (HLA) alleles 
[126]. But there is also an environmental factor, highlighted by the concordance rate of 
40-60% in monozygotic twins and also by the dramatic increase in T1DM incidence in 
the last decades [127, 128]. Currently the incidence of T1DM is rising faster than can 
be accounted for by genetic change. It has been suggested that the common challenges 
that our immune system used to face historically, such as microbes, worm infections 
and viruses have a role in down modulating certain autoimmune or allergenic responses 
[129-131].  
 
Type II Diabetes Mellitus (T2DM) also previously called Non-Insulin Dependent 
Diabetes Mellitus (NIDDM) is insulin insensitivity, meaning that the β-cells are 
producing insulin at normal or increased levels but the peripheral tissue insulin 
receptors are not sensitive to the hormone resulting in increased blood glucose levels. 
When the β-cells no longer can compensate for the peripheral insensitivity, diabetes 
occurs [132]. Even before the onset of T2DM there are metabolic abnormalities 
present, usually called the Pre-diabetic state, such as high blood pressure, abdominal 
obesity, lipid disorders and insulin resistance [133].  T2DM is becoming more common 
as the rates of childhood obesity increases. Reports of incidence rates of T2DM range 
between 17 and 49 cases per 100,000, with most new paediatric diagnoses documented 
among 15-to 19-year-old minority groups [134]. T2DM now accounts for 45% of the 
new cases of diabetes in the paediatric population [135]. Although the obesity epidemic 
is largely to blame for the rapid increase in T2DM, there is also a genetic component. 
The risk of T2DM is 40% if one parent has the illness, while in the general population 
it is 7%. Also, the sibling of a person with T2DM has 3 times higher risk of developing 
T2DM than the general population [136]. Several susceptibility genes have been 
identified. For example, the common Pro12Ala polymorphism in peroxisome 
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proliferator-activated receptor-γ (PPAR- γ) where a proline residue increase the relative 
risk of T2DM 1.25 fold compared to the alanine residue [137]. In the same pro12ala 
mutation in PPAR- γ, albuminuric persons carrying the proline residue had excess risk 
of worsening of their microalbuminuria compared to those with the alanine allele [138]. 
Another example is the KCNJ11 gene, coding for islet ATP-sensitive inward rectifier 
postassium channel 11, also known as Kir 6.2. A glutamic acid to lysine mutation at 
codon 23 is associated with an odds ratio of 1.18 for T2DM [139]. The mutation also 
causes decreased insulin secretion in non-diabetic subjects [140]. 
 
Adults with diabetes have a 5-10 years shorter life expectancy than non-diabetics due to 
vascular complications [141]. This increase in death rate is mostly due to a higher 
incidence of cardiovascular disease (CVD) in diabetic subjects. Macro-vascular injuries 
include stroke, ischemic heart disease and peripheral vascular disease. Micro-vascular 
injuries include retinopathy, neuropathy and nephropathy [118, 141]. The prolonged 
hyperglycaemia and dyslipidemia associated with diabetes promotes increased 
oxidative stress, inflammatory molecules and results in vascular damage [142].   
 
1.4.2 Diabetic nephropathy 
Diabetes is the most common cause of end stage renal disease (ESRD), and the 
prevalence of diabetes is rapidly increasing [117]. The vascular complications from 
diabetes cause chronic kidney disease (CKD), which can in turn develop into ESRD 
where dialysis or kidney transplant surgery are the only treatment options [143]. Once a 
patient has had to start dialysis the future is bleak, since about 2/3 of dialysis patients 
die within 5 years after starting the dialysis treatment [144]. The early detection of 
CKD is usually through microalbuminuria, sometimes just a few years after diabetes 
has been diagnosed. After another 5-10 years macroalbuminuria develops in those 
patients that are on the track to ESRD. During the next 5-10 years the kidney function 
starts to decline further and the glomerular filtration rate falls [145-147].  Usually the 
degree of proteinuria correlates well with tubulointerstitial fibrosis and 
glomerulosclerosis [148]. There is also an increased risk for cardiovascular disease in 
patients with DN [149]. The diabetic milieu causes activation of a number of metabolic 
pathways by glycated proteins, hyperglycemia, hemodynamic changes and the 
generation of reactive oxygen species (ROS) [150-153].  This in turn leads to a cascade 
of inflammatory cytokines and chemokines causing injury to podocytes, tubular 
fibrosis, thickening of the GBM and the accumulation of mesangial matrix.  One 
important downstream mediator of renal fibrosis and glomerulosclerosis is 
transforming growth factor-β (TGF- β), which acts by stimulating the production of 
collagen and vascular endothelial growth factor (VEGF) [154-156].  
 
To prevent the patient from heading down the path to ESRD, it is important to start 
treatment early in the pathogenesis. The first concern is treating the diabetes with oral 
hypoglycaemic agents or insulin injections to obtain normalized blood glucose levels 
and normalized Hb1Ac, a long time measure of blood glucose levels [157].  Good 
glycemic control is essential in halting the progression of DN [158]. Other treatments 
are directed at the renin-angiotensin system (RAS) as a major pathway in the 
development of DN [159]. RAS blockade has been shown to reduce damage to kidney 
[160], brain [161] and heart and to reduce cardiovascular mortality [162, 163]. The 
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hormonal cascade is initiated by circulatory or kidney produced renin catalyzing the 
conversion of angiotensinogen to angiotensin I. Angiotensin I is in turn converted to 
angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II can induce 
proliferation [164, 165], stimulate mesangial matrix accumulation and fibrosis through 
TGF- β induction [166, 167], generate ROS [168, 169] and affect renal blood flow 
through aldosterone [170]. RAS blockade can be obtained by ACE inhibitors or with 
angiotensin receptor blockers (ARBs) [171-173]. Statins (HMG Co-A reductase 
inhibitors) are used to treat dyslipidemia and work by inhibiting HMG Co-A reductase, 
the rate limiting enzyme in cholesterol synthesis. Statin therapy was hypothesised to be 
beneficial in DN because hyperlipidemia has been linked to glomerulosclerosis and 
tubulointerstitial fibrosis [174-176]. The effect of statin therapy on DN progression is 
not as clear cut as for the RAS blockade. Statins have only been showed to have a 
modest beneficial effect in cases of mild to moderate CKD [177], although they did 
have a good effect on cardiovascular disease [178, 179] and should therefore be 
considered for all diabetic patients who are at risk for vascular complications [179]. 
 
1.4.3 Animal models of diabetic nephropathy 
 
T1DM models: 
 
Several models are used to study diabetic nephropathy in T1DM. One model is the 
destruction of pancreatic β-cells by streptozotocin (STZ). Induction of diabetes occurs 
after injection of STZ, a chemical composed of two deoxyglucose molecules linked to 
nitrosourea. The compound is taken up by the β-cells and the nitrosourea reacts within 
the cells to form a nitrixoxide-based toxin that damages the DNA of the cell and causes 
necrosis [180]. Induction can be done by two methods; one high dose injection or 
several low dose injections. The high dose method requires about 150-200 mg/kg of 
STZ to induce chronic hyperglycemia. With this method substantial tissue toxicity may 
occur, including the nephrons [181, 182]. The low dose method uses multiple low dose 
injections of STZ leading to low grade β-cell damage, and lymphocyte infiltration to 
induce diabetes. Usually daily intra peritoneal injections of 35-50 mg/kg STZ are given 
for 5-6 days [183, 184]. The advantage of STZ is that it can be used to induce T1DM in 
transgenic models to study the effect of targeted genes on diabetes. A drawback of the 
model is that nephrotoxicity that has been reported from STZ treatment in mice [181, 
182, 185] as well as patients with islet cell carcinoma [186, 187]. Strict metabolic 
control has been shown to greatly influence renal function after STZ induction of 
diabetes  [188], and the model is still widely used. I used isolated glomeruli from low 
dose injected STZ mice in paper IV. 
 
The insulin-2 Akita (Ins2Akita) mouse is a mutant mouse model of T1DM [189-191]. 
The mutation is in the insulin-2 gene, causing misfolding of the protein and gradual β-
cell death. It is an autosomal dominant mutation where homozygosity for Ins2Akita 
leads to failure to thrive and death at 1-2 months of age. Heterozygot mice develop 
hyperglycemia, hypoinsulinemia, polydipsia, polyuria beginning at about 3-4 weeks of 
age. The hyperglycemia is worse in male mice than in females. Albuminuria is mild on 
the C57BL6 background and DN is described as “not robust” [40]. On a different 
genetic background, the KK background, the nephropathy was much more prominent, 
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with significant albuminuria, renal hypertrophy and a reduction in GFR at 20 weeks of 
age compared to the mutation on C57BL6 background [192]. 
 
One of the most well studied models of T1DM is the non-obese diabetic (NOD) mouse 
[193], which develop spontaneous autoimmune destruction of the β-cells due to 
abnormalities in the immune system at around 5 months of age [40]. The NOD mouse 
has a mutation in the major histocompability complex that causes diabetes to develop in 
60-80% of females and about 20% of males [194-196]. Symptoms are hyperglycemia, 
polyuria, polydipsia, glucosuria and hypercholesterolemia [193]. The NOD mouse is 
mostly used to study the development of diabetes, and is not commonly used to study 
secondary effects of diabetes such as diabetic nephropathy due to the late onset of 
diabetes and the need for daily insulin after onset [40]. 
 
FVB-OVE26 is a model of T1DM with early onset. The mutation is an insulin 
promoter-driven calmodulin gene that results in β-cell toxicity. The model develops 
significant albuminuria, an increase in GFR at the onset of diabetes and later a decrease 
as the DN progresses. Histopathology show thickened GBM, enlarged glomeruli and 
increased mesangial matrix [197]. The model is available from The Jackson 
Laboratory. 
 
A rat model is the bio-breeding (BB) rat. The model develops spontaneous T1DM due 
to abnormalities in the immune system. In the BB rat, 40% of the pups develop diabetes 
due to cell mediated autoimmunity [198-200]. Like the NOD mouse it is rarely used to 
study secondary effects of diabetes. 
 
T2DM models 
 
The db/db mouse has a mutation in the leptin receptor, leading to abnormal splicing and 
defective signalling [201]. The result is hyperphagia, high insulin and leptin levels and 
severe obesity. The mutation was initially found in the C57BLKS/J strain and has been 
backcrossed to pure C57BL/6J background as well. In the BLKS background 
hyperinsulinemia develops at 10 days of age, blood glucose levels are slightly elevated 
at 4 weeks of age and with frank hyperglycemia at 8 weeks. The hyperglycemia 
increases gradually until bodyweight and blood glucose levels begin to fall at 5-6 
months due to β-cell destruction [202, 203]. After 4 months of age there is a 3-fold 
increase in mesangial matrix expansion [204]. Albuminuria is reportedly between 68-
303 ug/24h in the male db/db and 4-21 ug/24h in controls [205, 206]. (In paper IV I 
report similar results with mean AER of 250, 208 and 215 ug/24 hours for db/db and 
13, 9 and 4 ug/24 for controls at 2, 4 and 6 months.) The susceptibility for diabetes is in 
the KS strain background, as the db/db mutation on the C57BL/6J background 
develops only mild hyperglycemia [204]. Although the DN may not be as robust on the 
C57BL/6J as it is on the C57BLKS/J background, the C57BL6/J background is easier 
to cleanly intercross with transgenic and knockout strains, since they are commonly 
available on this background. I used the db/db model to do the expression analysis in 
paper IV. 
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The ob/ob mouse is a mutation in the leptin gene, the ligand for the leptin receptor 
[207]. The model is commonly available on the C57BL/6J and renal lesions are 
reported to be very mild [40, 204].   
 
The agouti or Ay mouse has a mutation in agouti, a protein produced in the hair follicle. 
Aside from being a paracrine regulator of pigmentation of the fur [208] it also 
resembles agouti-related protein (Agrp), a potent antagonist for melanocortin receptors-
3 and -4 (Mc3r and Mc4r) expressed in the hypothalamus and involved in weight 
regulation and energy expenditure [209]. The Ay mouse expresses agouti protein 
ubiquitously from an alternative transcriptional promoter [210, 211]. The ectopically 
expressed agouti protein interacts with the Mc3r and Mc4r and leads to obesity, insulin 
resistance and albuminuria on the KK genetic background [212, 213].   
 
Strain dependence  
As implicated several times above, the sensitivity to diabetes and DN is dependent on 
the genetic background in the mouse strain. The most widely used C57BL6/J mice are 
prone to develop diet-induced obesity, hyperglycemia and hyperinsulinimea, they are 
relatively resistant to DN with low levels of albuminuria and glomerulosclerosis [49, 
214, 215].  DBA/2J mice in contrast are prone to develop albuminuria and 
glomerulosclerosis [49, 216], as are mice on a KK background [49, 217]. Non-diabetic 
mice on the BALB/c background are usually used as controls for KK mice [213]. 
Further studies are needed to broaden our knowledge of the genetics that make certain 
strains more susceptible to DN than others. 
 
 
1.5 MICROARRAY 
1.5.1 Transcriptional profiling  
With microarray technique it is possible to gauge patterns of gene expression by 
sampling thousands of genes in a single experiment. Most microarray experiments are 
designed to investigate the patterns of expression in related samples and to look for 
genes that are differentially expressed. Comparisons can be done between cells or 
issues that are treated/untreated, sick/healthy, fed/starving etc to provide information 
about which genes, pathways, cell types etc are involved in the biological process. The 
technique is based on the hybridization of a nucleic acid strand to another strand with a 
complimentary sequence of base pairs (bp). Complementary sequences of DNA, called 
probes, are attached to the surface on a slide (called a chip). The probes can be cDNA 
probes or oligonucleotide probes, based on the system used [218, 219].  Gene 
expression profiling can be used to find “finger prints” unique to a specific biological 
processes or illnesses, to classify and to predict the outcome in for example acute 
lymphoblastic leukemia[220]. 
 
1.5.2 cDNA and oligonuclucleotide microarrays 
In cDNA microarrays the probes are made up of amplified cDNA fragments of about 
500 bp in length. The cDNA is dissolved in a printing buffer and printed on glass slides 
as an array of spots. Each spot represents one gene. For cDNA arrays “two colour 
hybridization” is usually used, meaning that two RNA samples are labeled with 
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different fluorescent dyes and hybridized on the same slide. The ratio of fluorescence 
between the different dyes that hybridize to a spot then indicate the relative mRNA 
abundance between the two samples. The advantage of cDNA microarrays is that they 
can be manufactured and produced in-house and hybridization costs can be kept 
relatively low, compared to oligoarrays. The disadvantage is that there is an increased 
tendency for false positives from cross-hybridization due to the length of the probes, 
compared to the shorter probes on oligoarrays [221]. There is also a lack of control for 
sequence homologues. In paper II we constructed a cDNA microarray from isolated 
mouse glomeruli and used it to analyse gene expression in healthy glomeruli and in 
glomeruli from mice with a knockout of the gene Foxc2. In our hybridizations we used 
Cy-3 and Cy-5 flourescent dyes and performed two colour hybridization with one 
sample of interest hybridized against a reference sample of pooled mRNAs. The 
reference sample was used as a background to calculate different abundance of 
expression; similar to what is done for oligomicroarrays, to facilitate comparisons 
between all relevant samples. The reference design is described in Kerr and Churchill 
2001[222]. 
 
The most well known commercially produced oligomicroarrays are made by 
Affymetrix, GeneChip®. They are made by light directed chemical synthesis of 
nucleotide probes on the slide [223]. The Affymetrix oligoarrays consists of pairs of 
25-bp probes called probe pairs. Each probe pair consists of one probe that is a perfect 
match (PM) to the gene, and one probe that has a mismatch nucleotide in the middle of 
the probe is called a mismatch (MM) probe. The PM probe is designed to hybridize 
only with transcripts from the intended gene, giving specific hybridization. The MM 
probe is designed to measure the level of unspecific hybridization. Each gene is 
represented by 11-20 pairs of probes, called a probe set. Oligomicroarrays use “one 
colour hybridization” with only one biotin labelled sample being hybridized to each 
chip [224]. Oligomicroarrays are more expensive than cDNA arrays, but the density 
(number of genes tested) is usually much higher. For paper IV I used Affymetrix 
GeneChip® Mouse 430 2.0. The array has 45 000 probe sets to analyze over 39 000 
transcripts from more than 34 000 mouse genes. 
 
1.5.3 The experimental process 
The key to a successful expression analysis is good experimental design and attention 
to detail. There are many steps between sample preparation and data analysis, and each 
step has the potential to introduce errors and bias that would affect data analysis and 
interpretation of the results. To minimize this and have confidence in the results it is 
necessary to have the correct number of both technical and biological replicates in the 
experiment [225]. In general a minimum of 5 biological replicates is recommended, 
based on inbred animals. Outbred animals will increase the variance and the number of 
replicates should reflect this [224].  
 
The experimental process typically starts with the isolation of RNA from the biological 
samples, for example glomeruli isolated from diabetic and non-diabetic control mice. 
The quality and concentration of the RNA is tested. A method for testing is using the 
Agilent BioAnalyzer for standardization of RNA quality control, using an algorithm to 
calculate an RNA integrity number (RIN) [226].  If the quality of the RNA is high 
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enough, the RNA is amplified to cDNA, labeled and hybridized to probes on the arrays 
in a manner that allows for gene expression to be measured and compared between 
samples. This can be done either by using a single dye and individual arrays for each 
sample, or by using two differently dyed samples to be hybridized against each other on 
the same array. Data quality is essentially the same using either one colour or a ratio of 
two colours for hybridization [227].  
 
After hybridization the arrays are scanned and an image file is generated for each 
sample. The images are analyzed to identify the relative fluorescence intensities in each 
sample on an array. The hypothesis is that the fluorescence intensity for each arrayed 
gene is representative of its expression level. In the data preprocessing differences due 
to non-specific signal is corrected, questionable and low-quality measurements are 
removed and the measured intensities are adjusted in a processed called normalization 
to facilitate the comparisons in and between different hybridisations. The standard 
Affymetrix software MAS5 [228] uses the difference in signal between the PM probe 
and the MM probe in background adjustments, but in some cases the MM probe detects 
signal as well as non-specific binding, resulting in negative signal values and false-
negatives [229]. To adjust for this an alternative model called RMA was developed that 
ignored the MM probes in background adjustment. RMA is more sensitive in detecting 
differential expression, but the model tends to underestimate unspecific binding. To 
improve accuracy another algorithm was suggested, GCRMA, that adjust background 
based on probe sequence information [230]. In paper IV we used the GCRMA method. 
After normalization a number of genes that differentially expressed between samples 
can be identified. Modified t-tests have been developed for microarray analysis to test 
for statistical significance. A widely used test is Significance Analysis of Microarray, 
(SAM) [231]. If samples from many conditions are being compared Analysis of 
Variance, (ANOVA) can be used [232]. The statistics for microarray studies require 
compensation for the large numbers of genes being tested to avoid false positives. The 
array means that thousands of tests are performed simultaneously, and to set the 
threshold for statistical significance at p< 0.05 in an array with 10 000 genes would 
mean on average 500 false positive genes being selected as statistically significant by 
chance. To select the genes that are truly differentially expressed out of these 500, the 
p-values need to be adjusted to compensate for multiple testing. To compensate for 
multiple test errors and remove false positives multiple test correction a method called 
False Discovery Rate (FDR) is commonly used [233].  
 
To be able to discover patterns and groups of genes in the data set, the significantly 
differentially expressed genes are then classified into categories depending on their 
function, cellular location or biological process, to mention a few examples. KEGG is a 
database focused on pathways. It is available at www.genome.jp/kegg/  GOminer is 
another database that organizes genes into hierarchical categories based on biological 
process, molecular function or cellular component. The database is available at 
www.geneontology.org A very good tool for annotation is the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) [234], available at 
http://david.abcc.ncifcrf.gov   In paper IV we used the David tool to analyze patterns in 
gene expression.  
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2 AIMS 
 
 Paper I: To analyze the role of endothelium-derived Pdgfb in a conditional 
knock-out model 
 Paper II: To identify genes involved in glomerulus development and function 
 Paper III:  To analyze the role of pericytes in the blood-brain barrier 
 Paper IV: To analyze glomerular gene expression and markers of inflammation 
in diabetic mouse models 
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3 PRESENT INVESTIGATION 
3.1 PAPER I: ENDOTHELIUM-SPECIFIC ABLATION OF PDFGB LEADS 
TO PERICYTE LOSS AND GLOMERULAR, CARDIAC AND 
PLACENTAL ABNORMALITIES. 
 
Introduction: 
Platelet derived growth factor-B (Pdgfb) is instrumental in the development of a 
healthy, functional cardiovascular system. In this study we set out to study the 
importance of Pdgfb signalling in the vasculature using a Cre-lox system ablating 
Pdgfb expression specifically in endothelial cells [61]. Pdgfb and Pdgfrβ null mutants 
die perinatally due to microvascular problems manifested as edemas and hemorrages. 
Pdgfb -/- and Pdgfrβ -/- mutant vessels show frequent microaneurysms, abnormal 
endothelial ultrastructure, variable vessel diameter and signs of increased vascular 
permeability [59, 112]. Organs that appear to be extra sensitive and show specific 
defects include the kidney, heart and placenta [59, 60, 235]. In the kidney, mesangial 
cells express Pdgfrβ and need Pdgfb expressed from the endothelial cells to be properly 
recruited into the glomerulus. In the null mutants the mesangial cells are missing and 
the complexity of the glomerular tuft is replaced by a single capillary loop [79]. 
 
A conditionally inactive pdgfb gene was generated by incorporation of loxP sites on 
either side of exon 4. This resulted in a functionally intact pdgfb/flox allele. Mice 
homozygous for the pdgfb/flox allele were then crossed with pdgfb+/- mice expressing 
Cre under the endothelial cell promoter Tie1. This crossing generates Cre+Pdgfb-/lox 
endothelium restricted k.o mice (abbreviation: lox/-) as well as number of controls: 
Cre-Pdgfb+/flox (flox/+), Cre-Pdgfb-/flox (flox/-) and Cre+Pdgfb+lox (lox/+). 
Previous analysis by  Enge et al. showed that deletion of Pdgf expression was not 100% 
complete and subject to individual variation with an average of 70% recombination in 
the endothelial cell population [61]. The mice were born at the expected frequency, 
viable and fertile and lived into adulthood. 
 
Results and discussion: 
It has been reported that the Tie1 promoter drives expression of Cre in the glomerular 
tuft, and we confirmed expression in glomerular endothelial cells and tubular 
interstitium using the Rosa 26 reporter (R26R) strain and β-gal staining [79, 236]. By 
crossing Tie1Cre and R26R reporter mice and staining for β-gal the expression of Cre 
and the efficiency of the recombinase could be studied. About 70% of the cells were β-
gal positive, a ratio that is comparable to the ratio between recombined and 
uncombined floxed alleles in the brain capillary reported previously [61], suggesting 
that recombination in the presence of Cre takes place to the same extent in the R26 and 
pdgfb alleles. This also confirmed glomerular endothelial and peritubular expression as 
well as expression in the placental vessels. In the heart Tie1 expression was seen in the 
endocardium, cardiac valves and the endothelium. The large vessels such as the aortic 
arch showed chimeric expression. 
A reduction in Pdgfb protein levels was confirmed using Pdgfb-binding aptamers, 
confirming the fact that recombination at the pdgfb site leads to attenuated protein 
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levels in isolated glomerular fractions. Glomerulus isolation was done using the 
magnetic bead method developed by Takemoto et al. [237].  
 
Glomeruli in the endothelial specific Pdgfb k.o at embryonic day 18.5 (E18.5) resemble 
the Pdgfb null k.o and the PDGF-B retention motif k.o, with some glomeruli showing 
distension of the capillary loops from lack of mesangial cells, but the phenotype is 
milder and with more individual variation. The variation in the degree of severity 
coincided with the number of mesangial cells present in the glomerulus, which was 
confirmed by ASMA staining. ASMA staining showed the complete absence of 
mesangial cells in some glomeruli and the presence of a reduced cluster of ASMA 
positive mesangial cells in lox/- mice, leading to less complexity in the glomerular tuft 
and a dilation of the few remaining capillary loops. The individual variation in the 
phenotype was also apparent from the analysis of the glomerular capillary diameter. 
The diameter of the lox/- capillary was significantly larger than in all the control 
groups. At 3 weeks postnatally the mesangial cell deficiency was largely corrected but 
there was still a significant glomerular dilation both measured as increased diameter of 
the individual capillary and as an overall increase in glomerular diameter. By 6 months 
of age and older, no morphological signs of pathology could be detected. In mutants of 
PDGFR-β signaling and in the PDGF-B retention motif k.o accumulation of glomerular 
ECM have been noted [63, 238] but this was not seen in the endothelial cell specific k.o 
neither at 6 months nor at >12 months old when sections were stained by periodic acid-
Schiff’s (PAS) reagent.  
 
To investigate albuminuria, urine was collected over 24 hours in metabolic cages and 
analysed on a mouse-specific ELISA plate (Albuwell-M). In lox/- mice there was a 
small but statistically significant increase in urinary albumin compared to controls at 
>12 months but not at 6 months. This would suggest that despite the postnatal 
normalization of glomerular histology, some disturbances in the glomerular filtration 
barrier occur at an older age. Albuminuria, to our knowledge, is not mediated by 
mesangial cells primarily. Podocytes, endothelial cells or the composition of the GBM 
is probably influenced by the mesangial cells to cause the albuminuria. The level of the 
albuminuria, although statistically significant, is very low and probably not of 
pathological significance.  
 
The endothelial cell specific k.o also show cardiac abnormalities similar to what has 
been reported in the complete Pdgfb k.o, including dilation, myocardial hypnotherapy 
with thinning of the myocardial wall, myocardial hypertrabeculation and septal 
abnormalities [58, 59] at E 18.5. Like the glomerular phenotype, the hearts of postnatal 
ages 1 month, 6 months and >12 months appeared histologically normal and the 
myocardium had reached normal thickness. Also the placental abnormalities typical of 
Pdgfb -/- and Pdgfrβ -/- embryos were reproduced in the lox/- embryos with a dilated 
embryonic blood vessels and reduced numbers of pericytes and trophoblasts in the 
labyrinthine layer [235]. As was the case with the glomerular situation, the cardiac and 
placental malformations showed interindividual variation in the lox/- mice, in contrast 
to the Pdgfb and Pdgfrβ null mutants. The reason for this is probably in the chimeric 
expression of Tie1 Cre in the tissue resulting in variations in the deletion of Pdgfb. 
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The recruitment of pericytes to microvessels in the brain is also dependent on 
functional Pdgfb. To quantify brain pericyte content in the lox/- mouse, the Tie1 
Cre/Pdgf-b/flox alleles were crossed into the XlacZ transgenic background, in which 
LacZ is expressed in vascular smooth muscle cells and pericytes from late gestation and 
onwards. Quantification was done on midbrains after whole-mount β-gal staining in 
pdgf-b -/-. Lox/- and control animals. In the pdgf-b -/- the number of brain pericytes 
was reduced by more than 95% compared to controls, where as in the lox/- showed an 
intermediate phenotype with reduction of about 70-90%, with individual variation. 
Even in cases where the overall reduction was 90%, individual capillaries with normal 
pericyte coverage were found next to neighboring naked capillaries. This again reflects 
the chimeric situations where most capillaries are composed of Pgfb-negative 
endothelial cells where as some capillaries are composed of mostly unrecombined, 
Pdgfb-expressing endothelial cells capable of recruiting pericytes. 
 
Conclusions and future perspectives: 
The critical importance of Pdgfb in the recruitment of pericytes and vascular smooth 
muscle cells to blood vessels and in recruitment of mesangial cells to the glomerulus 
has been demonstrated previously.  This study identifies endothelial cells to be the 
essential source of Pdgfb in these cases, as well as a role in proper heart and placental 
development. The defects in heart and placenta could be secondary to the 
microvascular injuries resulting from the lack of Pdgfb during embryonic development, 
or be due to some direct effect of Pdgfb on for example placental trophoblasts or 
cardiomyocytes. 
 
The reasons behind the apparent glomerular recovery are unclear. One possibility is 
that Pdgfb is not the only factor regulating the mesangial content of glomeruli, and the 
lack of endothelial Pdgfb causes a delay rather than an irreversible block in mesangial 
cell recruitment. Another possibility is that non-endothelial sources of PDGF-B such as 
hematopoietic cells could substitute for lack of endothelial protein. In addition to the 
endothelium specific Pdgfb k.o, Enge et al. also generated a macrophage specific Pdgfb 
k.o and saw no vascular effects (unpublished data). This leads us to believe that the 
contribution of macrophages in providing a source of Pdgfb for recruitment of 
mesangial cells and pericytes to is probably limited.  Two other hematopoietic cell 
types capable of produce high levels of Pdgfb, monocytes and platelets, probably play a 
role in recruitment of vascular smooth muscle cells in atherosclerotic lesions and may 
be important in maintaining immune cell homeostasis in the vascular system [65, 66]. 
Their impact on mesangial cells and pericyte recruitment to endothelial cells seems 
limited, however. Another possible option is the compensation by more recently 
discovered members of the Pdgf family, such as Pdgfb or Pdgfc that could substitute 
for Pdgfb. However, injections with an inhibitory antibody directed at Pdgfd in the 
Pdgfb retention motif k.o at postnatal day 1 showed no effect on glomerular size, 
cellularity, mesangial cell proliferation or ECM content at termination on postnatal day 
7, indicating that the possible compensatory role of Pdgfd is limited, at least in the early 
postnatal development (unpublished data). Yet another option would be that the 
chimeric expression of Cre from the Tie1 promoter leaves a number of unrecombined 
cells still capable of production of Pdgfb, and that these cells “rescue” the glomerular 
phenotype. 
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If the endothelium is the critical source of Pdgfb, how come the lox/- mice are viable in 
contrast to the Pdgfb null mice? Again, this probably has to do with the chimeric 
expression of Tie1 Cre. Quantification of recombination frequency in microvascular 
endothelium fragments in the lox/- mice showed individual variation but a 
recombination of between 70-90% in most cases [61]. This correlates with the 
reduction in the number of brain pericytes seen in whole-mount β-gal staining in 
midbrain in this study, and is a marked contrast to reductions of >95% in the Pdgfb null 
mice. It appears from these observations that mice can tolerate up to 90% loss of 
pericytes without severe organ dysfunction, but when the loss is more extensive the 
mice die perinatally. A small number of lox/- mice actually do die perinatally, and these 
may represent the individuals where recombination takes place at a high enough 
efficiency to lead to loss of more than 90% of pericytes.  
 
In an attempt to overcome the variation caused by the chimeric expression of Tie1 Cre 
we instead crossed the mice to another endothelial cell specific Cre line, the Tie2 Cre. 
By doing this we hoped to find out if the Tie2 promoter would give less chimeric 
expression of Cre protein and thus causing a more severe phenotype. Unfortunately the 
expression of Tie2 Cre was chimeric as well and we did not observe any significant 
differences in phenotype between the two Cre models in an initial study (unpublished 
data). If other Cre models develop that show high endothelium specificity and high rate 
of recombination, it would be interesting to do further experiments to see if the 
phenotype in the endothelium specific k.o would mimic that of the null mutant, or if it 
would still be less severe due to expression from non-endothelial sources.  
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3.2 PAPER II: LARGE SCALE IDENTIFICATION OF GENES IMPLICATED 
IN KIDNEY GLOMERULUS DEVELOPMENT AND FUNCTION. 
 
Introduction: 
Knowledge of the glomerular transcriptome is limited and the identification of 
glomerulus specific and glomerulus enriched transcripts would provide a better 
understanding of the glomerular development and function as well as of the 
mechanisms involved in glomerular diseases. In this study we constructed a cDNA 
library from isolated mouse glomeruli, classified the contents and constructed the 
Glomchip, an in-house printed glomerulus-specific cDNA microarray chip. The 
microarray chip was used to identify a number of novel glomerular transcripts. In a 
series of experiments we performed comparative analysis on these transcripts and they 
were assigned to specific cell types and characterized as podocyte or mesangial 
cell/juxtaglomerular markers. Further study on podocyte marker Foxc2 revealed a role 
in podocyte differentiation and glomerular development. 
 
Results and discussion: 
RNA from isolated glomeruli from adult and newborn mice was used to produce a 
cDNA library. After sequencing, filtering out vector parts and short transcripts of less 
than 100 bps we blasted the sequences against the ENSEMBL mouse gene data base. 
We received 12 309 high quality hits representing 6053 different genes and 941 EST 
sequences. The libraries were PCR amplified, purified and printed, resulting the 
Glomchip. This would provide a very valuable tool in analysing glomerular gene 
expression. 
 
Our first experiment was to compare isolated glomeruli from 5-day old mice against 
non-glomerular kidney tissue. This experiment resulted in 357 genes and 63 ESTs that 
were significantly upregulated more than 2-fold in the glomerular tissue. 48 of these 
genes are known glomerular genes like podocyte markers nephrin (Nphs1), podocin 
(Nphs2), podocalyxin (Podxl), synaptopodin (Synpo), protein-tyrosine phosphatase 
receptor o (Ptpro, GLEPP1) and Wilm´s tumor protein (Wt1) as well as several genes 
known to be vascular endothelial markers. 
 
To subtract vascular markers we profiled isolated brain capillary and subtracted genes 
not significantly 2-fold upregulated in glomeruli. This left us with 143 genes and 34 
ESTs, containing most known podocyte markers as well as candidate glomerular 
markers. Most known endothelial cell markers were either enriched in the brain 
capillary tissue or not differentially expressed between glomeruli and brain capillary. 
 
To further assign the glomerulus enriched transcripts to cell type we FACs sorted GFP 
positive podocytes from 8-day old mice. In these mice GFP expression was activated 
under the Z/EG transgene by Cre recombinase expressed under the control of the 
podocin promoter [239]. Transcripts 2-fold or more upregulated in the GFP positive 
podocytes revealed 49 genes and 10 ESTs. In the non-podocyte (GFP negative) cells 18 
genes were upregulated. The remaining 76 genes and 24 ESTs were not significantly 
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differentially expressed more than 2-fold between podocytes and non-podocyte 
glomerular cells.  
 
A number of podocyte and non-podocyte specific glomerular transcripts were validated 
by In Situ hybridization (ISH). The podocyte specific genes picked for validation was 
semaphorin sem2 (Sem2), rhophilin1 (Rhpn1), cbp/p300-interacting transactivator 2 
(Cited2), protease inhibitor 15 (Pi15) and gene X in comparison with three known 
podocyte markers (Nphs2, Podxl and Foxc2) [240-242]. The selected novel mesangial 
cell markers selected were secreted frizzled-related protein 2 (Sfrp2), aldo-keto 
reductase family 1 member B7 (Akr1b7 and lim domain only protein 7 (Lmo7) in 
comparison with known mesangial, juxtaglomerular and endothelial transcripts insulin-
like growth factor binding protein 5 (Igfbp5), renin (Ren1) and endomucin (Emcn) 
respectively [243-245]. From the In Situ hybridization we could study temporal 
expression of our markers, since the kidneys of E18.5 mice contain glomeruli in several 
different developmental stages (comma shaped, s-shaped, capillary loop stage as well 
as mature). Foxc2 was the only podocyte marker expressed as early as during the 
comma shaped phase, where it is still too early to make morphological distinctions 
between prospective podocytes and tubular epithelial cells. Sem2, Pi15, Rhpn1, Gene X 
as well as known markers Nphs2 and Podxl appeared in developing podocytes in the s-
shaped stage. In the capillary loop stage and the mature glomeruli all markers were 
expressed. Both novel and previously characterized mesangial markers were expressed 
first during the capillary loop and mature stages with the exception of Sfrp2, which was 
expressed in epithelium at the comma and s-shaped stages and later switched to being 
expressed in mesangial cells in the capillary loop and mature stages. Expression of 
these markers was also seen in the smooth muscle cells at the juxtaglomerular 
arterioles. 
 
To examine the functional relevance of podocyte marker Foxc2 during nephron 
development we obtained Foxc2 -/- kidneys. At E18.5 the kidneys were smaller and 
had reduced number of glomeruli with fewer than normal capillary loops which were 
dilated and blood filled. In fact, the mutant glomeruli resembles the mesangial cell 
deficient glomeruli seen in Pdgf-B and receptor Beta deficient mice [59, 79]. To 
evaluate the mesangial cell content we performed immunohistochemistry (IHC) 
staining for mesangial markers NG2 (Cspg4), Pdgfrb and desmin in comparison with 
endothelial marker pecam and podocyte marker Nphs1. The IHC revealed that 
mesangial cells were present and expressing the markers at normal levels, but instead of 
forming a branched mesangial core connecting to the capillary loop nest, the mesangial 
cells remained in a compact cluster at the centre of the glomerulus. Transmission 
electron microscopy (TEM) confirmed the abnormal distribution of mesangial cells and 
revealed that the mesangial cells failed to make normal focal contact with the GBM. 
Podocyte foot processes and SD were not properly formed but podocytes were instead 
connected by adherence junction-like structures normally only seen in immature 
podocytes at the s- and cup-shaped stages. Endothelial cells were thick and lacking the 
fenestrations which normally develops at the capillary loop stage. The TEM findings 
suggest that the differentiation of podocytes and endothelial cells is arrested before the 
capillary loop stage in the Foxc2 -/-. Since Foxc2 is expressed early in glomerular 
development it might play a role in podocyte differentiation. To further investigate the 
transcriptional changes we hybridized Foxc2-/- glomeruli to Glomchip. This revealed 
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upregulation of 501 transcripts and downregulation of 232 transcripts by 2-fold or 
more. Some podocyte markers (Nphs2, Mabf, Cdkn1c and novel marker Rhpn1) were 
downregulated while others (Nphs1, Wt1, Cd2ap and novel markers Sem2, Pi15 and 
Gene X) remained unchanged. The selective downregulation of some podocyte 
transcripts argues against a general block in podocyte differentiation, considering fact 
that our ISH data showed that most podocyte transcripts were turned on 
simultaneously. Podocytes play an important role in creating and maintaining the 
GBM, so we wanted to also look at the deposition of matrix proteins and integrins in 
the Foxc2-/- mice using IHC. Expression levels of laminins, protoglycans as well as the 
podocyte expressed Integrin α3 chain were all normal. The collagen IV chains 
deposited during early glomerular development, Col4a1 and Col4a2 also showed 
normal deposition but there was a significant reduction in deposition of the collagens 
present in the GBM of a mature glomerulus, Col4a3, Col4a4 and Col4a5. This would 
suggest that the GBM fails to mature properly in the Foxc2-/- glomeruli. 
 
Conclusions and future perspectives: 
The construction of a glomerulus-specific cDNA chip enabled us to detect rare 
transcripts from highly specialized cells like podocytes, fenestrated endothelial cells 
and mesangial cells, transcripts that would otherwise drown in the noise of transcription 
from non-glomerular kidney cells. Since albuminuria as a result of injury to the 
glomerular filtration barrier leads to CKD, it is important to be able to analyze 
glomerular gene expression. The advantage of using isolated glomeruli instead of 
whole kidney allows us to monitor transcription in glomerular cell types making up 
only a fraction of the kidney mass. By this approach we characterized a number of new 
podocyte and mesangial/juxtaglomerular markers that could be potentially relevant in 
glomerulopathy. The disadvantages to our approach include the fact that the libraries 
were not sequenced to saturation, and thus there are glomerular transcripts missing in 
our libraries and on our cDNA chip. Also, transcripts that are not expressed by 
glomerular cells in the normal, healthy situation, but that are initiated when the 
filtration barrier is injured are not present on Glomchip. The same goes for transcripts 
from migrating cells from for example the immune system, which are not picked up by 
our chip for the same reason.  
 
In an attempt to investigate the functional relevance of genes picked up by Glomchip 
we analyzed transcription factor Foxc2-/- glomeruli using the chip and IHC. Foxc2-/- 
mice die embryonically and perinatally due to anomalies in the aortic arch and 
collapsed lungs. [246] The glomeruli from E18.5 Foxc2-/- mice displayed a failure to 
form multi lobulated glomerular tufts, lack of podocyte foot processes and SD, thick 
and unfenestrated endothelial cells and mesangial cells who failed to make proper 
contacts with the GBM and aid in splitting of the glomerular tuft vasculature. Since 
Foxc2 expression within the glomerulus is restricted to podocytes and we didn’t see 
differential expression of mesangial cell transcripts, we believe that the mesangial and 
endothelial cell defects are likely to be secondary to the podocyte defect and highlights 
the importance of signalling and communication between the glomerular cell types. 
The fact that expression of Col4a3, Col4a4 and Col4a5 are reduced in the Foxc2 is 
interesting, since mutations in these genes are responsible for Alport’s syndrome. It 
does not explain the podocyte differentiation defects in the Foxc2-/- glomeruli 
however, since experimental inactivation of Col4a3 and Col4a4 as well as Alport’s 
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syndrome results in delayed onset renal disease and glomeruli are morphologically 
normal during development [247-249]. The fact that Foxc2 is expressed already at the 
s-shaped stage of glomerular development, earlier than most podocyte markers, suggest 
that it may play a role in podocyte differentiation. The selective differential expression 
of podocyte transcripts in Foxc2-/- indicates that the mutation causes complex 
transcriptional changes and it is not possible to explain the podocyte differentiation 
defect by differential expression of a single known podocyte protein. Instead the defect 
is most likely caused by changes in a combination of genes that are directly and/or 
indirectly orchestrated by Foxc2. The complexity of the change in the transcriptional 
symphony is illustrated by the fact that more than 700 different genes in the glomeruli 
are affected by the mutation. To put this in context, transcriptional profiling of isolated 
glomeruli from Pod1-/-, using the Affymetrix Mouse Genome 430 2.0 chip, showed 
differential expression of 18 genes and thus have a very small effect on gene regulation 
during glomerular development [250]. It would be interesting to compare 
transcriptional profiles of other podocyte transcription factor mutants to look for 
overlap in podocyte target genes.   
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3.3 PAPER III:  PERICYTES REGULATE THE BLOOD-BRAIN BARRIER 
 
Introduction 
In this study we constructed a mouse model where a conditionally silent human Pdgfb 
(hPdgfb) gene was inserted into the ubiquitously expressed Rosa 26 locus [251]. The 
vector construct was a Splice Acceptor (SA) followed by loxP flanked intervening 
cassette containing the selection marker PGK Neo and four Poly-A sequences to 
terminate transcription. After the floxed selection/termination cassette is a cDNA copy 
of the human Pdgfb gene. When a mouse bearing the vector in the R26 locus is crossed 
with a mouse expressing Cre protein the Cre causes excision of the floxed termination 
cassette, leading to expression of hPdgfb in this specific cell type in the offspring. This 
mouse can be used to study the over expression of Pdgfb in selected tissues, or it can be 
used to create a hypomorphic Pdgfb model by rescuing the Pdgfb null mutant. Since the 
Pdgfb null mutant is perinatally lethal, a hypomorphic model is very useful in studying 
the effect of Pdgfb on pericytes in postnatal processes. A Pdgfb null mutant expressing 
one copy of the R26 hPdgfb gene turned on by endothelium specific Cre is here 
referred to as a hemizygous R26P+/0, while a null mutant expressing two copies of the 
hPdgfb is called a homozygous R26P+/+. Another example of a hypomorphic Pdgfb 
model is the Pdgfb ret/ret, where the cellular retention motif binding the Pdgfb protein 
to the ECM is deleted. This leads to changes in the extracellular distribution of Pdgfb 
protein and, as a result, to hypoplasia and partial detachment of pericytes from the 
vessel wall. We used both of these pericyte-deficient models to study the role of 
pericytes in maintaining the blood-brain barrier integrity in vivo.  
 
Results and discussion: 
Quantification of pericyte coverage in different regions of the brain using CD13 or 
Pdgfrβ staining revealed lower pericyte density of 26% in the pdgf-b ret/ret and of 40% 
in the R26P+/0. The corresponding figure for the R26P+/+ was 72%. Absolute 
quantification with the XlacZ4 reporter strain (a transgenic marker for migrating limb 
muscle precursor cells and vascular smooth muscle cells, see [252] ) confirmed the 
reduction of pericyte numbers in the Pdgfb ret/ret and the R26P +/-. There was also a 
reduced vessel density and dilation of the existing vessels in the pericyte deficient mice. 
The apical-basal polarity remained normal, as shown by staining for the luminal 
endothelial marker podycalyxin and the abluminal marker collagen IV.  
 
The brains of Pdgfb ret/ret and R26P +/- mice appear enlarged upon gross anatomical 
inspection and this was confirmed by measuring the wet/dry weight ratios of brains. 
This led us to suspect edema and impaired integrity of the blood-brain barrier (BBB). 
The BBB integrity was tested using a variety of injectable tracers, the first being the 
azo dye Evan’s Blue (EB), which binds to plasma proteins and is often used to trace the 
extravasation of albumin. EB was retained in the brains of the mutants to a degree 
corresponding to pericyte loss: the mutants with a more severe loss of pericytes 
retained more dye in the brain than animals with a more normal pericyte coverage. The 
ret/ret mice retained more EB than the R26P +/0 followed by the R26P +/+. To study 
possible size-selectivity in the leakage across the BBB a series of tracers with different 
molecular weight was used: 950kDa cadaverine Alexa Fluor-555, fluorescently labelled 
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66 kDa albumin, 70 kDa dextran and 200 kDa IgG. All of the markers crossed the BBB 
in the pericyte-deficient animals. A small amount of leakage was seen in the brain 
parenchyma of the R26P +/+ animals, but no leakage could be detected in the controls. 
These results show that there is a close correlation between pericyte coverage and the 
leakage of a range of tracers of different molecular weight across the BBB. 
To study mechanism behind the extravasation we analyzed the inter-endothelial 
junctional complexes in the pericyte-deficient mutants. By using markers for 
endothelial adherence junctions (VE-cadherin) and tight junctions (ZO-1 and Claudin-
5) we could see that the distribution and protein levels for these markers were quite 
similar in mutants and controls, with only subtle abnormalities. This was confirmed 
with TEM, which revealed no apparent abnormalities in the ultrastructure of the 
endothelial junctions in the mutants except that longer, irregular stretches of endothelial 
overlap was commonly found in the pericyte-deficient mutants. 
 
The endothelial accumulations of all the high molecular weight tracers were speckled, 
causing us to suspect that they were retained in intracellular vesicles in the endothelial 
cells. To further study this, we injected another high molecular marker, horseradish 
peroxidase (HRP) of 44 kDa and studied the distribution in TEM in ret/ret mice. We 
found increased localization of HRP to macro-vesicles in the mutants, while the uptake 
to micro-vesicles was similar in mutants and control animals. Our observations seem to 
indicate that high molecular weight molecules cross the BBB in pericyte-deficient 
mutants via macro-vesicular trancytosis. 
 
During stroke the BBB commonly opens and causes edema in the CNS, Using an 
experimental mouse model of stroke, this edema could be counteracted by 
administration of the tyrosine kinase inhibitor imatinib [253]. When we treated with 
imatinib, we could see almost completely reversed leakage of all tested tracers in our 
pericyte-deficient mutants in a dose-dependent manner. Interestingly, imatinib 
treatment seemed to result in retained uptake and enhanced punctuates distribution of 
tracer, implying that imatinib inhibits the release of tracer from endothelial cells. This 
suggests that imatinib works by inhibiting a mechanism involved in the exocytosis step 
of trancytosis.  
 
To analyze if pericytes regulate the endothelial expression of BBB markers, we used 
Affymetrix gene expression arrays to analyze transcription profiles of microvascular 
fragments from controls and pericyte-deficient mutants. The results showed that most 
BBB endothelial markers were unaffected by pericyte-deficiency, like most other 
endothelial specific mRNA transcripts. Thus pericytes do not seem to regulate BBB 
endothelial expression at a general level, but some markers showed altered expression 
levels. One example is transferrin receptor (CD 71), which was slightly downregulated 
in pericyte-deficient vessels, and this was confirmed on the protein level by staining 
brain tissue with an anti-CD 71 antibody. The unaltered expression of Glut 1 was 
confirmed using the same method. These results show that pericyte-deficiency can, at 
least in some select cases, influence the expression profile of BBB endothelial cells.  
 
Astrocytes are in constant contact with BBB blood vessels through cap-like cytoplastic 
processes called end-feet. Since pericytes are partially sandwiched between endothelial 
cells and the astrocyte end-feet, and since several astrocyte markers were 
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downregulated in pericyte-deficient mutants in our Affymetrix study, we wanted to 
investigate whether the lack of pericytes also lead to changes in the astrocyte end-feet 
distribution or polarization. We used three different astrocyte markers which all 
localize to the part of the astrocyte end-feet that contacts the endothelium: Aqp-4, α-
syntropin and laminin α2 (lama2). The vessel staining for all three markers was weaker 
in pericyte-deficient mutants than in controls. Interestingly, expression of Aqp-4 and α-
syntropin was associated with areas where pericytes had detached from the vessels or 
were extending between two different vessel branches. The staining pattern of staining 
for Aqp-4, α-syntrophin and lama2 is affected, indicating that the polarization of the 
astrocyte end-feet also is affected by the lack of pericytes. It would therefore seem like 
pericytes could be expressing cues that mediate the attachment of astrocyte end-feet to 
brain microvessels as well as aid in polarization.  
 
Conclusions and future perspectives: 
We successfully constructed a transgenic mouse with inducible expression of human 
Pdgfb from the Rosa-26 promoter. In this study the transgenic was used to create a 
hypomorphic Pdgfb model by crossing it with the Pdgfb null mutant. The Rosa 26 
transgenic can also be used to study the overexpression of Pdgfb by crossing it with a 
mouse expressing Cre protein. When crossed with the Tie2-Cre mouse, no significant 
differences in pericyte number were observed in adults. To see if there was an initial 
peak in pericyte number during development we looked in retinas at p7. There was a 
13% increase in LacZ positive pericytes around veins but no significant difference 
around arteries or in the capillary network between artery and vein. It seems that it is 
not possible to significantly increase pericyte numbers by just overexpressing Pdgfb at 
moderately high levels. (Armulik et al. unpublished data) 
 
Pericytes have previously not been thought to play a role in the formation of the BBB, 
but here we show for the first time that lack of pericytes causes leakage across the 
barrier as well as changes in expression of endothelial and astrocyte specific proteins in 
the BBB.  
 
We demonstrated that the integrity of the BBB is impaired in pericyte deficient mice, as 
injected tracers extravasate into the brain parenchyma. The extent of leakage correlates 
with the degree of pericyte deficiency. The route of extravasation appears to be through 
macromolecular trancytosis since markers for tight junctions and adherence junctions 
were largely normal. The speckled appearance of the high molecular weight tracers in 
endothelial cells suggested macromolecular trancytosis and this was confirmed by the 
distribution of HRP using electron microscopy. The tyrosine kinase inhibitor imatinib 
inhibits the exocytosis step of the trancytosis in a dose-dependent manner, and thus stop 
the leakage across the BBB.  
 
In our microarray study certain endothelial markers of the BBB was affected by the 
lack of pericytes, as well as some astrocyte markers affecting attachment of astrocyte 
end-feet to the vasculature. 
 
Despite the increase in endothelial trancytosis that causes brain edema and leakage of 
plasma proteins into the brain, these mice have a normal life span. This makes them an 
interesting model to further study the functional effects of an impaired BBB, both on 
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cognitive behaviour and learning and in studies on progression of brain diseases. The 
fact that immunoglobulins are able to cross the BBB in pericyte-deficient models is 
pharmacologically interesting. Further studies of the role of pericytes in maintaining the 
BBB should be of great interest. 
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3.4 PAPER IV: GLOMERULAR TRANSCRIPTOME ANALYSIS AND THE 
PRESENCE OF ALTERNATIVELY ACTIVATED MACROPHAGES IN 
DIABETIC NEPHROPATHY 
 
Introduction: 
The prevalence of diabetes is rapidly growing from 2.8% to 4.4% of the population 
worldwide [117]. The growing numbers have resulted in diabetic nephropathy (DN) 
being the number one cause of kidney disease in the world. In an attempt to broaden 
our understanding of the mechanisms behind DN, we used a model for T2DM, the 
db/db mouse, to perform expression analysis of isolated glomeruli from four different 
time points during the development and progression of albuminuria and 
glomerulosclerosis. The time points chosen were at 1 month, 2 months, 4 months and 6 
months of age. We used the DAVID tool to find KEGG pathways to gain insight into 
the transcriptional changes occurring during the development of diabetic nephropathy 
with albuminuria and glomerulosclerosis. We found a dramatic differential expression 
of genes involved in the in pathways relating to activation of the immune system, 
cellular adhesion and transendothelial migration of leukocytes. We also noted 
differential expression of pathways involved in the composition of the GBM and the 
extracellular matrix, such as collagens, laminins and fibronectin. At the top of the list of 
most upregulated genes was Chitinase 3-like 3 (Chi3l3), also called Ym-1, a marker for 
alternatively activated macrophages [254, 255].  
 
Results and discussion: 
Blood glucose levels were tested in age groups of 1 month, 2 months, 4 months and 6 
months (1m, 2m, 4m and 6m) and a statistically significant increase was found in the 
db/db from 2m.  Statistically significant albuminuria in the db/db group was found at 
2m, 4m and 6m of age using 24h urine collection cages and ELISA analysis for mouse 
albumin. The levels correlate well with previous findings in this model [205, 206]. 
RNA was isolated from glomeruli of db/db and control litter mates at all four time 
points and analyzed on Affymetrix GeneChip 430 2.0 arrays.  
 
Pathway analysis was performed to identify significantly different patterns of 
expression and several pathways were found to be significantly altered at each stage in 
the disease progression. For this analysis we used the DAVID tool to perform KEGG 
analysis [234]. 
 
Fourteen genes were significantly already before the onset of albuminuria and remained 
so at all time points in our study, starting already at 1m. Among these were the 
upregulated transcripts for Ym-1, ankyrin repeat domain 1 (Ankrd1), gastrin releasing 
peptide (Grp) and the downregulated calcitonin/calcitonin-related polypeptide alpha 
(Calca) transcript. The highest fold changes of all were found for Ym-1, where 
expression was upregulated 16-, 20-, 38- and 56-fold at 1-, 2-, 4- and 6-months of age. 
Ym-1 has been co-localized with Mac-1 and scavenger receptor, indicating 
macrophages as the main producers [256]. Ankrd1 is described in cardiac- and skeletal 
muscle cells where it acts as a messenger in mediating stress response [257, 258]. 
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Ankrd1 is also a regulator of gene expression in the nucleus, interacting with tumor 
suppressor gene p53. Ankrd1 acts as a co-activator of p53 and can upregulate the p53 
activity [259]. Ankrd1 has also been hypothesized as being involved in podocyte injury, 
as Ankrd1 protein expression in podocytes correlated positively with severe proteinuria 
in several different glomerulopathologies including DN [260]. In our study Ankrd1 was 
expressed at the mRNA level before the onset of albuminuria, suggesting that 
expression may be initiated even before the proteinuria. 
Grp is implicated as a morphogen in the progression of colorectal cancer [261]. The 
protein has been found in synovial fluid and serum of rheumatoid arthritis (RA) 
patients and the protein levels in synovial fluid and serum correlates with cytokine 
levels [262, 263]. Another neuropeptide, Calca, was significantly downregulated in all 
age groups. Calca protein has also been reported in higher levels in synovial fluid in 
RA patients than in control subjects [264, 265] but there was no correlation to plasma 
levels. Local expression of neuropeptides at sites of inflammation may play a role in 
regulating the recruitment of leukocytes into the tissue [266]. The differential 
expression of these neuropeptides in the db/db glomerulus suggests that neuropeptides 
may be involved in the regulation of leukocyte recruitment into the glomerular tissue 
before the onset of albuminuria and sclerosis. 
 
At 2-4 months the KEGG analysis shows changes in pathway involved in cell adhesion 
molecules and transendothelial migration. There is an upregulation of CD99, a protein 
present on blood monocytes and required for transendothelial migration [267], changes 
in expression of cellular adhesion molecules Claudin1, -15 and -16 and upregulation of 
filamin B, a molecular linker in the Icam1-driven transmigration of leukocytes [268], as 
well as Icam1 itself. There is also an increased expression of P-selectin, E-selectin and 
L-selectin and of Mac-1, the ligand for Icam1. CD45, a modulator of antigen signalling 
[269] is upregulated, as is Itga9 and Itb2, which together forms an integrin receptor 
expressed on leukocytes, implicated in cell migration and invasion [270]. Two potential 
ligands for the Itga9/Itb2 receptors, tenascin and fibronectin (Fn1) [271, 272], are 
upregulated at this time point as well. Together this suggests an increased trans-
migration of leukocytes into the glomerulus.  
 
Both vascular endothelial growth factor c (Vegfc) and Vegfd are upregulated and could 
be involved in focal adhesion and woundhealing [273]. Expression of Flt1, the receptor 
for another Vegf isoform, is increased as well. Flt1 is expressed on macrophages and 
acts as a positive regulator of inflammation by promoting macrophage migration 
towards its ligand, Vegfa [274]. Increased levels of Flt1 in the urine of diabetic patients 
correlate positively with increased albuminuria [275], suggesting a possible role for 
Flt1 in the recruitment of macrophages into the glomerular lesions. 
 
There was an increase in cytokine-cytokine receptor expression and compliment 
activation at 2-4 months as well, pointing towards active inflammation and the 
recruitment of leukocytes and antigen presenting cells (APCs) into the glomeruli. Both 
cytokine receptor Ccr1 and Ccr2 are upregulated. Ccr1 is the receptor for macrophage 
inflammatory protein-1 alpha (MIP-1alpha), RANTES and myeloid progenitor 
inhibitory factor-1 (MPIF-1) [276-278] on monocytes and APCs. Blockade of Ccr1 
reduces the infiltration of leukocytes and reduces inflammation and fibrosis [279, 280]. 
Ccr2 is the receptor for Ccl, formerly known as monocyte chemotactic protein-1 (MCP-
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1) [281]. APC such as monocytes and immature tissue macrophages express Ccr2 and 
blockade of the receptor has been effective in preventing macrophage recruitment in 
diabetic renal injury [282-284]. The upregulation of Ccr1 and Ccr2 again suggests 
macrophage infiltration. Csf and IL-4 in combination induces differentiation of 
monocytes into tissue macrophages [285]. Monocytes differienting into dendritic tissue 
macrophages are characterized by the expression of CD16, also known as Fc gamma 
receptor III (Fcgr3) [286, 287], a low affinity receptor for IgG. The IL-4 receptor alpha 
(IL4Ra), colony stimulating factor 1 receptor (Csf1r) and Fcgr3 are all upregulated at 
4m and 6m in our study, probably indicating increased differentiation of invading 
monocytes to tissue macrophages. IL-4Ra is the receptor for Il-4 and IL-13 [288-290], 
a cytokines known to induce expression of markers for alternative activation in 
monocytes and tissue macrophages. Two such markers are Ym-1 [291, 292] and 
coagulation factor XIIIA1 [293], both of which are strongly upregulated in our study.  
 
At 2 and 4 months the cell surface protein CD44 is upregulated along with P, E and L 
selectin. CD44 together with P and E selectin is involved in the intitiation of leukocyte 
trans-endothelial migration in inflamed vessels [294]. CD74 was also upregulated at 
this time. CD44 and CD74 form the CD44/CD74 receptor complex [295] on 
leukocytes. It binds macrophage inhibiton factor (MIF), an inflammatory cytokine, and 
signals to activate the downstream ERK 1/2 MAP kinase, leading to increased influx of 
macrophages and T-cells into the kidney [296]. The signal also causes downstream 
modulations in arachidonic acid metabolism and prostaglandin synthesis [296], and 
consistent with this we noted upregulation of leukotriene C4 synthase and 
prostaglandin I2 synthase in our data set. Increased expression of macrophage receptor 
complex CD44/CD74 and increased ERK 1/2 MAP kinase signalling in suggests 
increased macrophage density in the tissue. 
We also observed upregulation of plasminogen activator inhibitor 1 (PAI-1), previously 
linked to many complications in diabetes including glomerulosclerosis [297, 298], 
probably due to decreased degradation of plasmin in the ECM [299] and dysregulation 
of Fn1 expression [297].  
 
Also at 2-4 months, we noted changes relating to the composition of the extracellular 
matrix (ECM) and GBM including the upregulation of Fn1 and collagen5 alpha 1 
(Col5a1) and laminin alpha 5 (Lama5). Lama5 is expressed by glomerular podocytes 
and is a necessary component f a functional glomerular filtration barrier [300]. Col1a2 
and Lamc2 were downregulated. Col1a2 deficiency in the mouse model for 
osteogenesis imperfecta leads to accumulation of collagen fibrils in the mesangium and 
albuminuria [301]. Lamc2 is known t be a component in the GBM, but its role in the 
mature GBM is not known [302]. The changes we observed in the GBM and ECM may 
lead to the accumulation of mesangial matrix as well as disturb glomerular function. 
 
At 6 months, late in the progression of diabetes several components of the complement 
system were upregulated, including C1qa, C1qb and C1qc components, their receptor 
C1r and C3. Activated C1q can bind to pathogen-associated molecular patterns 
(PAMPs) as part of the innate immune system or the complement system can be 
recruited by the adaptive immune system. All three C1q subcomponents were highly 
upregulated, as was C1r, indicating that the complement system was active and 
bridging the innate immunity and acquired immunity. The upregulated transcript for 
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lymphocyte cytosolic protein 2 (Lcp2) is a partner of another upregulated transcript, 
Vav1. Together they are part of a “signalosome” that signals over the T-cell receptor 
and its costimulatory receptor CD28 to induce proliferation, IL-2/IL-4 production and 
Ca(2+) flux [303, 304]. Also upregulated Tyrobp (also called DAP12) is a trans-
membrane receptor expressed on several lymphoid and myeloid cells including 
macrophages, B-cells and T-cells under inflammatory conditions [305]. There was 
upregulation of leukocyte immunoglobulin-like receptor B3 (Lilrb3). It is expressed on 
cells of monocytic lineage, T-cells, B-cells and NKT-cells and is a negative regulator of 
inflammation [306]. CD79b, a protein necessary for expression and function of the B-
cell antigen receptor [307] was downregulated at the same time, possibly suggesting a 
reduction in B-cell receptor activity in the diabetic kidney.  Another indication of this is 
the fact that the B-cell marker CD20 was downregulated as well. When analysed 
together, the upregulation of transcripts involved in signalling in lymphocytes seem to 
indicate that at this late point in diabetes (6 months) the cells involved in innate 
immunity has likely activated both T- and NKT-cells of the acquired immunity, 
possibly through complement, and there is an influx of T-lymphocytes in addition to 
the myeloid cells. There is also a possible reduction in B-cell activity and 
differentiation.  
 
The most strongly and consistently upregulated gene in our time course study was Ym-
1, with 16-fold, 20-fold, 38-fold and 56-fold upregulation at 1, 2, 4, and 6 months of 
age. The upregulation on an mRNA level was confirmed using quantitative PCR 
(qPCR) in 2m and 4m old animals. Immunohistological staining with a rabbit 
polyclonal anti-mouse Ym-1 antibody in kidneys from db/db animals and controls 
showed strong fluorescent staining of solitary cells in the glomerulus but also a more 
diffuse staining in proximal tubuli. The glomerular staining for Ym-1 was consistent 
with infiltrating monocytes/macrophages. The staining in proximal tubuli prompted us 
to investigate if the Ym-1 staining in tubuli reflected expression of Ym-1 protein in 
tubular cells or uptake in tubular cells of protein expressed by glomerular macrophages 
and released into the urine. To address this question we performed qPCR comparing 
the expression in isolated glomeruli and remaining kidney tissue in db/db and control 
animals at 1 month of age. Expression in glomeruli was 23.6-fold higher in glomeruli 
than in remaining kidney tissue in db/db, indicating that the expression was from 
macrophages in glomeruli and that staining in proximal tubuli is most likely a result of 
tubular uptake of the Ym-1 protein. Also, there was no statistically significant 
difference in tubular Ym-1 mRNA expression between db/db and controls. To 
investigate whether Ym-1 positive cells were generally found in other organs in the 
db/db model we also performed immunohistological staining on muscle, liver, heart, 
lung and spleen and we observed no differences in expression between db/db and 
control animals, indicating that the infiltration of Ym-1 expressing cells in the db/db is 
glomerulus specific. To evaluate whether the presence of Ym-1 expressing 
macrophages in the db/db was related to diabetes or to other confounding factors such 
as obesity or genetic background, we investigated the mRNA expression of Ym-1 in 
isolated glomeruli from 4 and 6 month old STZ diabetic mice. We found 268-fold 
upregulation in STZ-diabetics compared to control animals and at 6 months the 
difference was 10.5 fold. The dramatic change in fold change between 4 months and 6 
months is in fact due mostly to that expression of Ym-1 was almost undetectable at 4 
months in the control animals, but detectable at low levels in control animals at 6 
months. In an attempt to see if Ym-1 protein would be detectable in urine, we 
performed Western Blot on fresh urine. A distinct band of approximately 44.3 kDa was 
observed in urine from 6 month old db/db animals but not in controls, suggesting that 
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Ym-1 can be used as a non-invasive urinary marker of infiltrating alternatively 
activated macrophages in the kidney.  
 
Ym-1 is a single chain secreted polypeptide of 398 amino acids [308]. Co-expression 
with macrophage markers Mac-1 and Scavenger Receptor defines macrophages as its 
main producer [256]. Ym-1 is considered a marker for alternatively activated 
macrophages [291, 292, 309].  
Classically activated macrophages (caMac) are characterized as being stimulated by 
interferon-gamma (INF-gamma) followed by a microbial trigger such as 
lipopolysaccaride (LPS), resulting in the release of pro-inflammatory cytokines IL-6, 
IL-1, an increase of TNF and a nitrixoxide (NO) burst [310]. These events in turn lead 
to an enhanced ability to kill and degrade intracellular microorganisms but also to tissue 
damage of the host itself [254, 311]. Classically activated macrophages have been 
postulated as having a pathogenic role in DN by secreting proinflammatory cytokines 
such as IL-1, IL-6, IL-12, TNF-alpha, CCL-2, CCL-3, CCL-4, Reactive Oxygen 
Species (ROS) and NO leading to microbicidal tissue inflammation, scarring and 
fibrosis [282, 312]. 
Alternatively activated macrophges (aaMac) are characterized by as being activated by 
IL-4 and IL-13 and their secretion of Ym-1, mannose receptor and scavenger receptor-
1. Secretory products and potential biomarkers include cytokines induced by IL-4 such 
as Retnla (Relm-alpha) also called FIZZ1, Factor XIIIA and Amac-1 [291-293, 313, 
314] (Reveiwed by Mosser et al in [315] and Gordon in [254]). Alternatively activated 
macrophages are thought to have anti-inflammatory effects and lead to cellular 
regeneration and tissue remodeling [316] and may even contribute to the repopulation 
of damaged glomerular and tubular cells and have a protective effect on the kidney 
[317, 318]. 
The strong and consistent upregulation of Ym-1 mRNA in our study prompted us to 
look at the expression of other macrophage expressed genes in an attempt to understand 
whether we could distinguish between different suptypes of macrophage populations in 
the diabetic glomerulous. We did not observe differential expression of genes in the 
cluster for classical activation such as iNos (Nos2), Ifn-gamma, Il-6, Il-1 or Tnf. The 
ratio of iNos/Arginase is often used to distinguish between caMac and aaMac. We did 
not observe significant changes in expression of these components, but instead was 
found significant upregulation of Ym-1, coagulation factor XIIIA, IL-33, Il-1R and IL-
4R, indicating the presence of aaMac [315, 319, 320] in the diabetic glomeruli. 
 
Conclusions and future perspectives: 
The differentially expressed genes in our study can be divided into three, albeit 
overlapping categories: changes in GBM/ECM , inflammation/innate immunity, and 
signal transduction/growth factors/transcription factors. The KEGG pathway analysis 
highlights immune response factors such as cytokines, monocyte and leukocyte 
receptors and adhesion molecules involved in leukocyte migration into the glomerulus, 
stressing the role of the immune system in DN. Other differentially expressed 
transcripts in the db/db mouse glomeruli include genes involved in the composition of 
the GBM and the extracellular matrix, e.g. collagens, laminins and fibronectin. Changes 
in the basement membrane synthesis and composition and the accumulation of 
mesangial matrix may disturb glomerular function and cause albuminuria. The 
combination of these three events is likely linked together in the development of DN. 
One obvious hypothesis coming out of our analysis is that networks of genes/proteins 
are causally related to the pathogenesis of DN. 
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Macrophage infiltration and inflammation have been implicated in the development of 
DN in several publications. Previous studies have not attempted subtyping of 
macrophages in diabetic kidneys into alternatively activated (aaMac) or classically 
activated (caMac), but studied expression of universal macrophage markers like CD68 
[282, 321] and F4/80 [280]. It is important to increase our knowledge of the detailed 
immunological components and processes involved in DN. In current therapies the 
immunological aspects of the illness are not treated and if macrophage-mediated injury 
is an important component in the development of DN, it is crucial that alternative 
therapeutic approaches are developed.   
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4 FINAL CONCLUSIONS 
 
Paper I: 
Endothelial cells are an essential source of Pdgfb in the recruitment of pericytes and 
vascular smooth muscle cells to blood vessels and in the recruitment of mesangial cells 
into the kidney glomerulus. 
 
Paper II: 
The construction of a glomerulus-specific cDNA microarray chip enabled us to detect 
rare glomerular transcripts and provided us with a better understanding of glomerular 
development as well as of the mechanisms involved in glomerular disease. 
 
Paper III: 
Injected tracer molecules cross the BBB via macromolecular trancytosis in pericyte-
deficient mice, demonstrating a role for pericytes in maintaining the integrity of the 
BBB. 
 
Paper IV: 
Expression analysis of glomeruli from diabetic db/db mice demonstrated dramatic 
upregulation of genes involved in activation of the immune system as well as in the 
composition of the GBM and ECM, stressing a role for the immune system in the 
development of DN.  
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